| Authors: |
Campling J; Pfizer Limited, Walton Oaks, Dorking Road, Tadworth Surrey, KT20 7NS, UK., Begier E; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA., Vyse A; Pfizer Limited, Walton Oaks, Dorking Road, Tadworth Surrey, KT20 7NS, UK., Hyams C; Bristol Vaccine Centre, Schools of Cellular and Molecular Medicine and of Population Health Sciences, University of Bristol, Bristol, BS2 8AE, UK.; Academic Respiratory Unit, Learning and Research Building, Southmead Hospital, Bristol, BS10 5NB, UK.; Acute Medical Unit, Southmead Hospital, Bristol, BS10 5NB, UK., Heaton D; Harvey Walsh, Open Health Group, Marlow, Buckinghamshire, SL7 2FF, UK., Southern J; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA., Finn A; Bristol Vaccine Centre, Schools of Cellular and Molecular Medicine and of Population Health Sciences, University of Bristol, Bristol, BS2 8AE, UK., Madhava H; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA., Gessner BD; Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA., Ellsbury G; Pfizer Limited, Walton Oaks, Dorking Road, Tadworth Surrey, KT20 7NS, UK. |